New Center Provides Lincoln Citizens the Opportunity to Give the Gift of
LINCOLN, Neb., July 31 /PRNewswire/ -- Today, Grifols Biomat USA celebrates the grand opening of a new plasma donor center in Lincoln, Nebraska. The Lincoln center located on 2002 N Street is one of 60 Biomat USA center to be opened in the United States and the first in Nebraska. The plasma donated at the Lincoln center is then used by Biomat USA's parent company Grifols to produce life-saving medicines.
Plasma is part of the blood that contains proteins and antibodies that are needed to fight infection and help stop bleeding, among other things. In the U.S. alone, it is estimated that over one hundred thousand people receive medicines made from human plasma each year. Plasma collected at Biomat USA plasma centers is used to produce these therapies such as: intravenous immune globulin (IVIG) to treat primary immunodeficiency; blood clotting factors to treat hemophilia and other bleeding disorders; and albumin, used for shock, trauma, and burns. For these conditions and others, regular and life-long treatment with a plasma therapy is the only treatment option.
Marcia Boyle, Immune Deficiency Foundation President, Founder and mother of a son with a primary immunodeficiency remarked "Since the production of IVIG, and other plasma therapies, begins with the donation of human plasma, Lincoln's donors play a vital role in maintaining an adequate supply of plasma needed to produce these life-saving plasma treatments. Because of these donors, countless people, such as my son, who depend on IVIG, and other plasma therapies, can live healthy and productive lives."
Not only does each Biomat USA Center serve a global mission of being an integral part in the production of life-saving medicines but each donor center also serves locally by providing vital economic and community service contributions. The Lincoln Center currently employs 32 local citizens and plans to hire an additional thirteen as the center grows. In addition, the Center will contribute close to $1.6 million annually to the Lincoln economy and most importantly has the capacity to process 1500 donors a week.
"The demand for plasma therapies has been increasing over the last few years and maintaining a readily available supply of plasma is essential to assuring continuous production of these much needed life-saving medicines," said Shinji Wada, President of Biomat USA. "Our strategy for opening new centers is focused on securing a stable supply of plasma in order to meet the needs of the expanding market," Wada said.
About Grifols Biomat USA:
Grifols Biomat USA is part of a large a network of plasma collection centers owned and operated by Grifols, a global healthcare company headquartered in Barcelona, Spain. Today, Grifols' plasma therapies are used to treat patients in more than 90 countries around the world. More information about Grifols Biomat USA and Grifols can be found at http://www.grifols.com.
|SOURCE Grifols Biomat USA|
Copyright©2008 PR Newswire.
All rights reserved